Amedisys (AMED) PT Raised to $60 at Baird Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Benchmark Downgrades Amedisys (AMED) to Hold
November 9, 2017 9:28 AM ESTBenchmark downgraded Amedisys (NASDAQ: AMED) from Buy to Hold.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Shares of Amedisys closed at $58.49 yesterday.
... MoreAmedisys (AMED) PT Raised to $64 at Jefferies
November 8, 2017 8:35 AM ESTJefferies raised its price target on Amedisys (NASDAQ: AMED) to $64.00 (from $60.00) while maintaining a Buy rating following Q3.
Analyst Brian Tanquilut said the 5% SS increase in Medicare episodes highlights early traction the company is seeing with its revamped sales force and growth initiatives.
... More